http://orcid.org/0000-0002-9538-0565
References
- Ananthakrishnan R, Gona P. (2010). Pharmacological modeling and biostatistical analysis of a new drug. Open Access J Clin Trials 2:59–82.
- Baek I-H, Lee B-Y, Kim M-S, Kwon K-I. (2013). Effect of food intake on the pharmacokinetics of sarpogrelate and its active metabolite following oral administration to beagle dogs. Xenobiotica 43:895–900.
- Baek IH, Lee BY, Kang J, Kwon KI. (2015). Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs. JVetPharmacolTher 38:199–202.
- Barakat N. (2006). Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation. Drug DevIndPharm 32:865–76.
- Brater D, Lasseter K. (1989). Profile of etodolac: pharmacokinetic evaluation in special populations. Int J Clin Rheumtol. 8:25–35.
- Brocks DR, Jamali F. (1994). Etodolac clinical pharmacokinetics. Clin Pharmacokinet 26:259–74.
- Budsberg SC, Johnston SA, Schwarz P, et al. (1999). Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 214:206–10.
- Cayen MN, Kraml M, Ferdinandi ES, et al. (1981). The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab Rev 12:339–62.
- Center for Drug Evaluation and Research (CDER), 2001. Guidance for industry, Bioanalytical method validation, US FDA. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070107.pdf. (Accessed 21 November 2016).
- Court MH. (2013). Canine cytochrome P450 (CYP) pharmacogenetics. Vet Clin North Am Small Anim Pract 43:1027.
- D’Argenio, DZ, Schumitzky, A, Wang, X. (2009). ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles, Biomedical Simulations Resource.
- De Miranda Silva C, Rocha A, Tozatto E, et al. (2016). Enantioselective analysis of etodolac in human plasma by LC-MS/MS: application to clinical pharmacokinetics. J Pharm Biomed Anal 120:120–6.
- Jelliffe RW, Schumitzky A, Van MG, et al. (1993). Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 15:380–93.
- Jones RA. (1999). Etodolac: an overview of a selective COX-2 inhibitor. Inflammopharmacology 7:269–75.
- Kletting P, Glatting G. (2009). Model selection for time-activity curves: the corrected Akaike information criterion and the F-test. Z Med Phys 19:200–6.
- Kraml M, Cosyns L, Hicks D, et al. (1984). Bioavailability studies with etodolac in dogs and man. Biopharm Drug Dispos 5:63–74.
- Lascelles BDX, Mcfarland JM, Swann H. (2005). Guidelines for safe and effective use of NSAIDs in dogs. Vet Ther 6:237–51.
- Luna SP, Basílio AC, Steagall PV, et al. (2007). Evaluation of adverse effectsof long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res 68:258–64.
- Meineke I, Türck D. (2003). Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. Br J Clin Pharmacol 55:32–8.
- Murata K, Noda K. (1994). Pharmacokinetics of multiparticulate sustained‐release diltiazem preparations in dogs. J Pharm Sci 83:38–41.
- Nishihara K, Kikuchi H, Kanno T, et al. (2001). Comparison of the upper gastrointestinal effects of etodolac and aspirin in healthy dogs. J Vet Med Sci 63:1131–3.
- Reimer ME, Johnston SA, Leib MS, et al. (1999). The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Int Med 13:472–7.
- Surdyk KK, Sloan DL, Brown SA. (2012). Renal effects of carprofen and etodolac in euvolemic and volume-depleted dogs. Am J Vet Res 73:1485–90.
- Tougou K, Gotou H, Ohno Y, Nakamura A. (2004). Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica 34:449–61.
- Zhang X, Li Q, Ye M, et al. (2018). Preparation, characterization and in vitro/in vivo evaluation of oral time-controlled release etodolac pellets. AAPS Pharm Sci Tech 19:610–20.